-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AIlD8ozHHIMnp1O172HgkgMi41CbI5GR2sk6cNf+fJXlwBy5lpIlG07PiJre7CvW fvBgkazyoBvlbpiP4Q+e+w== 0000312651-95-000016.txt : 19951213 0000312651-95-000016.hdr.sgml : 19951213 ACCESSION NUMBER: 0000312651-95-000016 CONFORMED SUBMISSION TYPE: 10KSB PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19950831 FILED AS OF DATE: 19951212 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: GOLDEN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000312651 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 840645174 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10KSB SEC ACT: 1934 Act SEC FILE NUMBER: 000-09065 FILM NUMBER: 95600882 BUSINESS ADDRESS: STREET 1: 1313 WASHINGTON AVE CITY: GOLDEN STATE: CO ZIP: 80401 BUSINESS PHONE: 3032799375 MAIL ADDRESS: STREET 1: 1313 WASHINGTON AVENUE CITY: GOLDEN STATE: CO ZIP: 80401 FORMER COMPANY: FORMER CONFORMED NAME: BENEDICT NUCLEAR PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 10KSB 1 [TYPE] 10-KSB [ARTICLE] 5 [LEGEND] This schedule contains summary financial information extracted from the registrants financial statements for the year ended August 31, 1995 contained in its annual report on Form 10-KSB and is qualified in it's entirety by reference to such financial statements. [/LEGEND] [PERIOD-TYPE] YEAR YEAR [FISCAL-YEAR-END] AUG-31-1995 AUG-31-1994 [PERIOD-END] AUG-31-1995 AUG-31-1994 [CASH] 49,557 94,792 [SECURITIES] 0 0 [RECEIVABLES] 1,484,175 310,307 [ALLOWANCES] (63,700) (1,063) [INVENTORY] 674,955 52,356 [CURRENT-ASSETS] 2,656,600 952,584 [PP&E] 2,736,714 2,052,181 [DEPRECIATION] (1,659,768) (1,555,033) [TOTAL-ASSETS] 8,079,905 1,515,489 [CURRENT-LIABILITIES] 2,040,931 428,703 [BONDS] 0 0 [COMMON] 21,288,851 21,246,351 [PREFERRED-MANDATORY] 0 0 [PREFERRED] 292,558 292,558 [OTHER-SE] (20,469,509) (21,359,368) [TOTAL-LIABILITY-AND-EQUITY] 8,079,905 1,515,489 [SALES] 4,412,377 3,451,020 [TOTAL-REVENUES] 4,412,377 3,451,020 [CGS] 2,245,230 1,584,864 [TOTAL-COSTS] 2,245,230 1,584,864 [OTHER-EXPENSES] 1,255,645 1,037,502 [LOSS-PROVISION] 0 0 [INTEREST-EXPENSE] 140,330 83,949 [INCOME-PRETAX] 787,303 752,552 [INCOME-TAX] (91,594) (500,000) [INCOME-CONTINUING] 878,897 1,252,552 [DISCONTINUED] 0 0 [EXTRAORDINARY] 99,677 76,560 [CHANGES] 0 0 [NET-INCOME] 978,574 1,329,112 [EPS-PRIMARY] .01 .01 [EPS-DILUTED] .01 .01
-----END PRIVACY-ENHANCED MESSAGE-----